title: Therapy for symptoms in the carcinoid syndrome.
abstract: The clinical course and results of drug treatment for manifestations of the carcinoid syndrome are reviewed in 63 patients. The five-year actuarial survival in this group of patients was 48 per cent. The only markers of a poor prognosis that could be identified at diagnosis were marked weight loss and a high (over 1000 mumol/day) 5-hydroxyindole acetic acid excretion. The relative effectiveness of well-established drugs that either block 5-hydroxytryptamine synthesis or block 5-hydroxytryptamine receptors is reported, with respect to the different manifestations of the syndrome, and compared with a small group of patients treated with long-acting somatostatin analogue. In over one-third of patients, primary tumours were not detected on initial investigation, and in none of these did symptoms referrable to the primary site become apparent later.
authors: Department of Medicine, Royal Postgraduate Medicine School, Hammersmith Hospital, London.
authors: M
authors: M
authors: Coupe
authors: S
authors: S
authors: Levi
authors: M
authors: M
authors: Ellis
authors: B
authors: B
authors: Clarke
authors: J A
authors: JA
authors: Morris
authors: E A
authors: EA
authors: Alstead
authors: D J
authors: DJ
authors: Allison
authors: H J
authors: HJ
authors: Hodgson
mesh_terms: D000328:Adult; D000368:Aged; D003967:Diarrhea / Q000188:drug therapy; D004621:Embolization, Therapeutic; D006801:Humans; D008303:Malignant Carcinoid Syndrome / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D010166:Palliative Care; D012702:Serotonin Antagonists / Q000627:therapeutic use; D015996:Survival Rate
chemical_list: D012702:Serotonin Antagonists